Targets Lp(a) at Its Source
Olpasiran is a small interfering RNA (siRNA) that works by blocking the production of Lp(a) in your liver.
1 in 5 people have High Lp(a)- a genetic cholesterol that may increase your risk of a heart attack by 300%. Get tested today to see if you qualify for a clinical trial evaluating an investigational treatment meant to prevent a first major heart event run by Dr. Powell and the Denali Health team!
Complete this form to see if you may qualify for the study.
“Great experience Love the staff Highly recommend”
Darius Bennet
Patient
“My providers were very welcoming, considering, and knowledgeable. I look forward to my future care.”
Steve Lee
Patient
“The staff was wonderful I will recommend Denali to my friends”
Vivian Franklin
Patient
“The best crew ever very helpful and nolejable”
Mohammad Samhouri
Patient
“The free transportation and compensation made it so easy to attend my appointments. The team was professional and caring throughout my entire treatment.”
Marcus M.
Patient

Principal Investigator
Dr. Powell is a physician researcher dedicated to advancing cardiovascular care through clinical trials. "Heart disease remains a leading health concern," he says. "We're committed to finding new ways to protect people at higher risk."
MPH, MD
Leading heart health clinical trials
Dedicated to safe, compassionate research
"Research gives us hope for better ways to prevent heart disease. Every participant who joins us helps advance what we know about protecting hearts."
And most don't know it because it's not included in standard cholesterol tests
Elevated Lp(a) significantly increases your risk of stroke and heart disease
Most doctors don't regularly test for Lp(a), and it's rarely covered by insurance
Most people don't know their Lp(a) levels. Join our research study and get comprehensive testing—completely free, no insurance required.
Fill out our quick pre-screening form. Tell us a little about yourself and your cardiovascular health history. Our team will contact you within 24 hours.
Visit our Plant City clinic for a simple blood draw. You'll receive comprehensive testing including Lp(a), lipid panel, A1c, and more. Plus, $100 compensation for your time.
Within a few weeks, our team will share your results, explain what they mean for your heart health, and provide a copy for your doctor. If eligible, learn about the study.
✓ No insurance required • ✓ Free comprehensive testing • ✓ $100 compensation
This is a Phase 3 global research study testing olpasiran, an investigational medication that targets Lp(a) production in the liver. With 1 in 5 people having elevated Lp(a)—often without knowing it—this study aims to see if lowering Lp(a) can help prevent first major heart attacks, strokes, or urgent heart procedures.
Lipoprotein(a), or Lp(a), is a genetic protein in your blood that builds up regardless of diet or exercise. Unlike other cholesterol, you can't control it with lifestyle changes. High Lp(a) increases stroke risk by 60%, yet 90% of doctors don't regularly check it. It's typically not included in standard cholesterol tests.
Adults with elevated Lp(a) levels and risk factors like high blood pressure, high cholesterol, diabetes, family history of heart disease, or smoking. If you have high Lp(a) and want to contribute to critical research that could help future generations, we'd like to hear from you.
If you have elevated Lp(a) and cardiovascular risk factors, you may qualify for this study.
A full evaluation will determine if the study is safe and right for you.
An investigational approach to lowering Lp(a) and reducing cardiovascular risk
Olpasiran (AMG 890) is an investigational medication using RNA interference technology to block Lp(a) production in your liver. Since Lp(a) is genetic and not affected by diet or exercise, this targeted approach may help reduce cardiovascular risk for people with elevated Lp(a). High Lp(a) can't be controlled with lifestyle changes or standard cholesterol medications, and there are currently no approved Lp(a) treatments on the market. Olpasiran is not yet FDA-approved.
Olpasiran is a small interfering RNA (siRNA) that works by blocking the production of Lp(a) in your liver.
The study aims to see if lowering Lp(a) can help prevent heart attacks, urgent heart procedures, or death from heart disease.
You'll receive regular health monitoring, blood tests, heart checks (ECGs), and safety assessments throughout the study.
The study drug is given as an injection under the skin about every 3 months (every 12 weeks).
No insurance required. All study care, monitoring, and Lp(a) testing provided free. Compensation and travel support included.
You will receive $100 for each completed study visit. Payments are provided for your time and commitment, whether you receive the study medication or placebo.
Free transportation to and from study visits. If travel is difficult, our team can help arrange transport.
All study-related care is provided at no cost. Study medication (or placebo), Lp(a) testing, blood work, ECGs, physical exams, and monitoring — all free. No insurance needed, no charges for any study visits or procedures.
Experienced research team providing careful monitoring and safety assessments throughout screening, treatment, and follow-up periods.
Find answers to common questions about our clinical research study.
20% of the world's population has elevated Lp(a), a very sticky protein (cholesterol) in your blood that is affected by genetics instead of lifestyle. Unlike other cholesterol, you cannot control it with diet or exercise. A lipoprotein(a) test can help determine your Lp(a) levels, however, it is typically not covered by insurance and not included in standard cholesterol tests.
Call or text +1 (813) 796‑6716. Or email info@denali-health.com. Travel expenses reimbursed to help you get here.
1601 W Reynolds St STE 203
Plant City, FL 33563
Mon–Fri: 8am–5pm
Sat: 9am–1pm (by appt)
Travel expenses reimbursed
Free parking available
Schedule a call or get directions to our office.
Complete this form to see if you may qualify for the study.